Published Online
on February 18, 2002

A more recent version of this article appeared on March 12, 2002

This Article Full Text (PDF) All Versions of this Article: 105/10/1214    most recent hc1002.105128v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Itescu, S. Articles by Edwards, N. Search for Related Content PubMed Articles by Itescu, S. Articles by Edwards, N. Related Collections CV surgery: transplantation, ventricular assistance, cardiomyopathy

Submitted on September 7, 2001
Revised on December 28, 2001
Accepted on January 3, 2002

Intravenous Pulse Administration of Cyclophosphamide Is an Effective and Safe Treatment for Sensitized Cardiac Allograft Recipients

Silviu Itescu MD^*, Elizabeth Burke RN, Katherine Lietz MD, Ranjit John MD, Donna Mancini MD, Robert Michler MD, Eric Rose MD, Mehmet Oz MD, and Niloo Edwards MD

From the College of Physicians and Surgeons of Columbia University, New York, NY.

^* To whom correspondence should be addressed. E-mail: si5{at}columbia.edu.

Background—The proportion of cardiac transplant recipients with preexisting sensitization to HLA alloantigens has been increasing. Sensitization prolongs duration to obtaining a donor and predicts poorer long-term allograft survival because of increased risk of cellular rejections. We investigated the effect of cyclophosphamide pulse therapy in sensitized cardiac allograft recipients.

Methods and Results—Pretransplant and posttransplant outcomes were compared between 88 cardiac allograft recipients at risk for sensitization and 26 sensitized recipients treated with intravenous cyclophosphamide pulse therapy together with intravenous immune globulin before transplant and as part of a cyclosporine-based triple immunosuppressive regimen after transplant. Preformed IgG anti-HLA antibodies predicted longer duration to transplantation, earlier cellular rejection, and 2.7-fold higher cumulative rejection frequency (P=0.002). Before transplant, cyclophosphamide reduced waiting time and mortality to levels in nonsensitized patients. After transplant, cyclophosphamide prevented induction of IgG anti-HLA class II antibodies and interleukin-2 receptor--positive T-cell outgrowth from biopsy sites (both P<0.01), prolonged the rejection-free interval (P=0.009), and reduced cumulative rejections to levels in nonsensitized patients (P=0.003). By multivariable analysis, the risk of rejection was 3.7-fold higher in patients treated with mycophenolate mofetil than patients treated with cyclophosphamide (P=0.019). There were no differences in infectious or other significant complications.

Conclusions—Immunosuppression incorporating intravenous cyclophosphamide before and after transplantation is safe and highly effective in sensitized cardiac transplant recipients. When used after transplantation as part of triple immunosuppression, cyclophosphamide is superior to mycophenolate mofetil in reducing rejection. The mechanism may involve prevention of diversification of the recipient immune response to donor HLA class II molecules.

Key words: transplantation • grafting • antigens • rejection • cells

This article has been cited by other articles:

				Q.-q. Wang, Y.-g. Qiu, Y.-j. Zhu, J.-h. Zhu, L.-h. Wang, X.-s. Hu, S.-j. Hu, L.-r. Zheng, Q.-m. Tao, F.-r. Zhang, et al. Cyclophosphamide protects against myocardial ischemia/reperfusion injury in rats: One of the therapeutic targets is high sensitivity C-reactive protein J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 991 - 996. [Abstract] [Full Text] [PDF]

				J. Zhu, Y. Qiu, Q. Wang, Y. Zhu, S. Hu, L. Zheng, L. Wang, and Y. Zhang Low dose cyclophosphamide rescues myocardial function from ischemia-reperfusion in rats Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 661 - 666. [Abstract] [Full Text] [PDF]

				S. G. Drakos, A. G. Kfoury, J. W. Long, J. C. Stringham, T. C. Fuller, K. E. Nelson, B. K. Campbell, E. M. Gilbert, and D. G. Renlund Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann. Thorac. Surg., September 1, 2006; 82(3): 889 - 893. [Abstract] [Full Text] [PDF]

				M. E. C. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. S. Kashmiri, J. Schlom, and H. Sabzevari Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood, April 1, 2005; 105(7): 2862 - 2868. [Abstract] [Full Text] [PDF]

				J. A. Crompton Transplant Immunology Journal of Pharmacy Practice, December 1, 2003; 16(6): 373 - 379. [Abstract] [PDF]

				S. Itescu and R. John Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications Ann. Thorac. Surg., June 1, 2003; 75(90060): S58 - 65. [Abstract] [Full Text] [PDF]